Over the past two decades, in response to mounting failures, clinical trials of disease-modifying therapies (DMTs) in Alzheimer’s disease (AD) have progressively moved earlier in the disease spectrum to increase the probability of success; today, most Phase III clinical trials enroll patients with “early AD,” commonly comprising mild cognitive impairment (MCI) due to AD (a.k.a. prodromal AD) and mild AD dementia (e.g., MMSE scores ≥ 22). Given the increasing awareness and sensitivity about earlier diagnosis and management of the disease, it is essential to understand how neurologists perceive the performance of current therapies in early patients, especially their expectations for an emerging DMT for early AD on key clinical and nonclinical attributes.
Markets covered: United States, United Kingdom, France, and Germany.
Primary Research: Survey of 60 U.S. neurologists and 30 European neurologists.
Key Drugs Covered: donepezil, galantamine, rivastigmine patch, memantine, Namzaric, gantenerumab, BAN2401, elenbecestat.
Key metrics included:
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.